• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Industrials·2355.HK
Share

Baoye Group Company Limited Stocks

HK$ 3.2Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

HK$ 217.78M

HK$ 3.2
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Baoye Group Company Limited, along with its affiliated entities, provides an extensive range of construction services across the People's Republic of China. The company's business activities are structured across three primary divisions: Construction, Property Development, and Building Materials. Within its Construction segment, the company undertakes the building of government and public facilities, urban amenities, and infrastructure, as well as commercial, residential, and industrial properties. This division also handles the integration of electrical and electronic systems, fire protection installations, and exterior curtain wall systems. The Property Development arm is dedicated to the creation and subsequent sale of real estate assets. Concurrently, the Building Materials division supplies a diverse array of products, such as curtain walls, ready-mixed concrete, various interior finishing items including furnishings, decorations, wooden goods, and fire-resistant materials, in addition to precast concrete (PC) assembly boards and other construction components. This segment also offers renovation and refurbishment services, architectural and interior design consultations, manufactures and erects steel frameworks, and produces and distributes machinery parts and precast concrete elements. Furthermore, it sells steel, fire-rated wooden doors, and other timber products, and is involved in the construction of highways, bridges, and other civic infrastructure projects. Established in 1974, Baoye Group Company Limited maintains its principal office in Shaoxing, People's Republic of China.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, underpriced o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 01:43

The S&P 500 and the Dow closed higher amid falling oil prices

27.07.2026 23:55

"Just Like a Nike Sneaker Drop": Ford Has Figured Out How to Boost Profits Through Customization

27.07.2026 23:27

Dior's owner reported an increase in sales of clothing and handbags for the first time in two years

27.07.2026 22:53

Nvidia formed an AI safety alliance following an accidental hack carried out by OpenAI

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026